ESSA Pharma Inc., a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that on April 18, 2018 the board of directors of the Company passed a resolution to proceed with the previously announced consolidation of the issued and outstanding common shares of the Company on a basis of one (1) post-Consolidation Common Share for every twenty (20) pre-Consolidation Common Shares
April 19, 2018
· 8 min read